In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Trinity Delta view: MaxCyte is approaching a landmark with the first regulatory filings for a programme under an SPL. We anticipate a first regulatory decision by year-end 2023 at the earliest. If approved, and pending payor/reimbursement discussions, the first launch of an SPL asset could occur in 2024. Exa-cel approval would have a major impact on MaxCyte’s FY24 revenues given that milestones for BLA/MAA approval are understood to typically be mid-seven figures (potentially per major region), ...
Indexes Form Bear Flag Patterns Within Downtrends We continue to view the price action over the past month as a bear market bounce in the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM), as each index appears to be forming a bearish flag pattern. Until the S&P 500, QQQ, and IWM can break above their YTD downtrends, we remain bearish, and believe investors should be using rallies to reduce overall exposure in preparation for new lows ahead... see charts below. U.S. Dollar, 10-Yr Treasury Yiel...
Signs of Disinflation? A bear market bounce is underway after the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM) found support at their respective downtrend channels, a possibility we discussed last week. Still, until the S&P 500, QQQ, and IWM can break above their various downtrends, we remain bearish, and believe investors should be using rallies to reduce overall exposure. Signs of Disinflation? We are starting to see early signs that inflation is peaking, as commodity prices have pulled...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
S&P 500 Downtrend Channel Intact & Testing Support We see the S&P 500 as trading within a downtrend channel; as long as it remains within this channel, our intermediate to long-term outlook is bearish at the index level. With that said, the S&P 500 is currently testing support within the downtrend channel, and we are on watch for a potential bear market rally. S&P 500. Last week, on May 18th, the NYSE had a 93% downside volume day, effectively negating the May 13th 92% upside day. Still, the 3...
10-Year Treasury Yield Testing 40-Year Resistance; Upgrading Health Care to Overweight Whether or not the lows for this correction have already been established remains to be seen, but evidence is mounting that suggests a test of the lows, and possibly a break to new lows, is increasingly likely. Regardless, continue to stick with the commodity and defensive Sectors, all of which hit new price and RS highs in recent days. 10-Year Treasury Yield. We have discussed our expectations for rising ra...
Not Out Of The Woods In last week's Compass we noted that on Monday Jan. 24, the % of stocks in the S&P 500 and Russell 2000 above their 50-day moving averages hit 19.8% and 10.7%, respectively, and that these levels have historically been consistent with a bullish short-term reversal. The short-term bullish reversal is officially underway now that the S&P 500 has reclaimed its 200-day MA, but we are not yet out of the woods; in today's report we discuss what we are watching to determine whethe...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
The independent financial analyst theScreener just lowered the general evaluation of VERTEX PHARMA INC (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 19, 2021, the closing price was USD 185...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.